

# 14th ANNUAL

## STATE OF THE HEART SYMPOSIUM



## 2 VIRTUAL SESSIONS:

Wednesday, May 24, and 31, 2023  
7:30 – 9:10 pm EDT

### PROGRAM

The State of the Heart program has been specifically designed for family physicians, specialists, nurse practitioners, nurses, pharmacists, technicians, and other allied health professionals who have an interest in cardiovascular disease and diabetes.

This program covers the latest topics in cardiovascular and metabolic disease, guidelines, late-breaking clinical trial results, and addresses patient care issues encountered in daily practice.

### AGENDA

#### SESSION 1 – May 24, 2023

##### Conference Program

7:30 pm	Opening Comments	
7:33 pm	<b>Heart failure: Does ejection fraction matter anymore?</b> <i>- Explore the importance of ejection fraction in the management of heart failure</i>	Peter Liu
7:51 pm	<b>HFrEF: What is the standard of care in 2023?</b> <i>- Describe appropriate management strategies and therapies for heart failure in 2023</i>	Michael McDonald
8:09 pm	<b>Chronic kidney disease: New treatments to improve outcomes -</b> <i>Recognize the role of newer treatments to improve outcomes for patients with chronic kidney disease</i>	Louise Moist
8:27pm	<b>Is it time for more widespread pharmacologic treatment of obesity?</b> <i>Examine the appropriate use of medication to support patients with obesity.</i>	Sean Wharton
8:45 pm	Panel discussion with Q &A	All Faculty
9:10 pm	Closing Remarks	

This 1-credit-per-hour Group Learning program has been certified by the College of Family Physicians of Canada and the Ontario Chapter for up to 1.75 Mainpro+ credits.

#### SESSION 2 – May 31, 2023

##### Conference Program

7:30 pm	Opening Comments	
7:33 pm	<b>Approaching a decade of PCSK9 inhibition - effects on CV mortality</b> <i>- Identify the long-term impact of PCSK9 inhibitors on CV mortality</i>	Milan Gupta
7:51 pm	<b>Inclisiran twice yearly: A new paradigm for lipid-lowering</b> <i>- Define the role of inclisiran in lipid management</i>	Jacques Genest
8:09 pm	<b>Lp(a): When to measure it and what to do about it</b> <i>- Describe when and how to use Lp(a) for risk assessment</i>	Michelle O'Donoghue
8:27pm	<b>Has the time come to treat inflammation to improve CV outcomes?</b> <i>- Describe the role of inflammation on CV outcomes and management options</i>	Paul Ridker
8:45 pm	Panel discussion with Q &A	All Faculty
9:10 pm	Closing Remarks	

This 1-credit-per-hour Group Learning program has been certified by the College of Family Physicians of Canada and the Ontario Chapter for up to 1.75 Mainpro+ credits.

**Accreditation:** This 1-credit-per-hour Group Learning program has been certified by the College of Family Physicians of Canada and the Ontario Chapter for up to 3.5 Mainpro+ credits.

### PLANNING COMMITTEE



Co-chair

#### Dr. Milan Gupta

MD, FRCPC, FCCS, FACC, FAHA  
Associate Clinical Professor  
University of Toronto  
Medical Director, Canadian  
Collaborative Research Network  
Brampton, ON



Co-chair

#### Dr. Jacques Genest

MD, CM, FRCPC, FACC, FAHA  
Professor of Medicine, McGill University  
McGill/Novartis Chair in Medicine,  
McGill University Health Centre/Royal Victoria  
Hospital,  
Montreal, QC



#### Dr. Christine Palmay

MD, CCFP  
Western University Schulich School of Medicine  
Physician, Midtown Health & Wellness Clinic  
Toronto, ON



#### Dr. Anil Maheshwari

MD, CCFP, DABOM, DABFM  
Executive Health Physician & Medical Director  
Weight & Lifestyle Program Cleveland Clinic  
Canada  
Family Physician & Obesity Program Clinical  
Lead  
Grandview Medical Centre Family Health Team  
Assistant Clinical Professor (Adjunct), McMaster  
University  
Medical Advisor for Canada - Unraveling Obesity  
OntarioMD Peer Leader  
Hamilton, ON



#### Dr. Laura Reardon

MD, CCFP, ABOM Diplomate  
Medical Director, Lotus Health Clinic  
Diplomate, American Board of  
Obesity Medicine  
Halifax, NS

Register free online at:  
[www.ccrnmmd.com](http://www.ccrnmmd.com)  
or use this QR code:



For inquiries regarding this program, please contact [info@ccrnmmd.com](mailto:info@ccrnmmd.com)

This program received unrestricted educational funding from Amgen and Boehringer Ingelheim Canada

